Application value of dexmedetomidine and midazolam combined with ultrasound-guided brachial plexus block anesthesia in patients with humeral fractures

This study aims to compare the efficacy and safety of dexmedetomidine and midazolam in patients undergoing humeral fracture surgery. Patients who underwent humeral fracture surgery in our hospital from July 2015 to December 2023 were retrospectively selected. Among the ultrasound-guided brachial plexus nerve block anesthesia protocol, 71 cases used midazolam and were included in Group A, 83 cases used dexmedetomidine and were included in Group B. The fluctuations of heart rate and mean arterial pressure in Group B were smaller than those in Group A. The onset time of sensory and motor block in Group B was shorter than that, while the maintenance time of sensory and motor block was longer. The sedative effect was higher (0.5 hours) after the start of the operation and at the end of the operation in Group B. The pain degree of Group B at 2, 8 and 12 hours after the operation was lower. The cognitive functions in Group B were higher at 30 minutes and 24 hours after the operation. There was no significant difference in the incidence of adverse reactions between the two groups. Dexmedetomidine can be given priority as an anesthetic drug for humeral fracture surgery.